📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
Wanbury FY26 Net Profit Surges 116% to ₹66.13 Crore; Revenue Up 8.5%
Wanbury Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with net profit more than doubling to ₹66.13 crore from ₹30.53 crore in FY25. Annual revenue grew 8.5% to ₹650.27 crore, driven by steady operations. A key highlight is the 18.9% reduction in finance costs to ₹29.98 crore, suggesting improved financial health and debt management. Q4FY26 profit also showed strength at ₹21.70 crore, despite a marginal year-on-year decline in quarterly revenue.
Key Highlights
Full-year FY26 Net Profit jumped 116.6% to ₹66.13 crore compared to ₹30.53 crore in FY25.
Annual Revenue from Operations grew to ₹650.27 crore in FY26 from ₹599.51 crore in the previous year.
Finance costs significantly reduced to ₹29.98 crore in FY26 from ₹36.95 crore in FY25, aiding bottom-line growth.
Q4FY26 Net Profit stood at ₹21.70 crore, up from ₹20.26 crore in Q4FY25.
The company reported an exceptional item loss of ₹3.60 crore during the quarter and year ended March 31, 2026.
👀 What to Watch
The sharp increase in profitability and reduction in interest burden are strong positives for the company's valuation; investors should monitor if the company can sustain these improved margins and accelerate revenue growth.
Wanbury's Patalganga Site Receives Zero Observations from Korea FDA (MFDS)
Wanbury Limited has successfully completed a regulatory inspection by the South Korean Ministry of Food and Drug Safety (MFDS) at its Patalganga facility. The three-day inspection, conducted between April 7 and April 9, 2026, concluded with zero observations, confirming full cGMP compliance. This adds to the company's track record of clean inspections, following zero observations from the USFDA for Patalganga and Anvisa for its Tanuku plant. Furthermore, the company is expanding its API manufacturing capacity with a new block in Andhra Pradesh currently under validation.
Key Highlights
Patalganga facility cleared the MFDS (Korea FDA) inspection with zero observations.
The 3-day regulatory audit was conducted from April 7 to April 9, 2026.
Both Patalganga and Tanuku sites maintain USFDA compliance with a history of zero observations.
A new state-of-the-art manufacturing block for APIs is being commercialized at the Andhra Pradesh site.
👀 What to Watch
The successful audit strengthens Wanbury's position in regulated international markets and reflects high manufacturing standards. Investors should monitor the commercialization of the new API block in Andhra Pradesh as a potential catalyst for revenue growth.
Wanbury Limited FY26 Compliance Report: Resolves Past Board Issues & Promoter Demat
Wanbury Limited's Secretarial Compliance Report for FY 2025-26 indicates the resolution of several significant past governance lapses. The company has successfully dematerialized 100% of promoter holdings and restored the required board and committee compositions, which previously led to fines exceeding ₹51 lakh. While a minor delay in filing the September 2025 shareholding pattern resulted in a ₹42,480 fine, the company is now largely in compliance with SEBI regulations. This transition suggests an improvement in administrative discipline compared to previous years.
Key Highlights
Paid a fine of ₹42,480 for delayed submission of the shareholding pattern for the quarter ended September 30, 2025.
Achieved 100% dematerialization of promoter shareholding, resolving a previous deficiency where only 76.74% was in demat form.
Restored Board of Directors to the required minimum of 6 members and Audit/NRC committees to 3 members by January 2025.
Settled substantial historical fines including ₹37.99 lakh for board composition and ₹10.57 lakh for NRC composition lapses.
Confirmed compliance with Secretarial Standards (SS) and all other major SEBI regulations for the review period.
👀 What to Watch
Investors should view the resolution of past governance issues as a positive step, but remain cautious due to the company's history of administrative delays and fines. Monitor future filings to ensure the company maintains its restored board and committee structures consistently.
Wanbury Launches New Pediatric Products to Target ₹861 Cr Cold Preparation Market
Wanbury Limited has launched Coriminic CPM Drops and Coriminic NS Nasal Drops to align with recent DCGI regulations restricting fixed-dose cold combinations for children under 4 years. This strategic move allows the company to protect and grow its presence in the ₹861 crore Cold Preparation Liquid market. By introducing standalone formulations that avoid restricted combinations, Wanbury is positioning itself as a first-mover in safer pediatric care. The launch is expected to consolidate the company's market share in the fast-growing pediatric therapeutic segment.
Key Highlights
Launched Coriminic CPM Drops and Coriminic NS Nasal Drops specifically for pediatric use.
Strategic response to DCGI restrictions on Chlorpheniramine + Phenylephrine combinations for children under 4.
Targets a significant share of the ₹861 crore Cold Preparation Liquid market in India.
First-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, regulation-aligned format.
Strengthens the established Coriminic brand portfolio through localized and non-systemic relief options.
👀 What to Watch
Investors should view this as a proactive move to safeguard revenue from regulatory risks in the pediatric segment. Monitor the company's ability to gain prescription share from physicians transitioning away from restricted fixed-dose combinations.
Wanbury Gets Brazil ANVISA Approval for Sertraline Form II and Rs 15 Cr Metformin Order
Wanbury Limited has received ANVISA approval from Brazil for Sertraline Form II, which complements its existing Form I approval. The company currently holds a dominant 75% market share for Sertraline in Brazil, and this new approval is expected to further consolidate its position. Additionally, the company secured approval from a major customer for a special Metformin DC grade, representing a potential revenue opportunity of Rs 15 crore per annum. Both manufacturing sites in Patalganga and Tanuku remain cGMP compliant, ensuring steady production capabilities.
Key Highlights
Received ANVISA (Brazil) approval for Sertraline Form II to strengthen market dominance.
Currently holds a 75% market share for Sertraline in the Brazilian market.
Secured a new Metformin DC grade approval with an estimated Rs 15 crore annual business potential.
Manufacturing facilities at Patalganga and Tanuku confirmed as cGMP compliant.
Approval for Form II is expected to further consolidate the company's share of business in Brazil.
👀 What to Watch
Investors should note the company's strong market position in Brazil and the incremental revenue from the new Metformin order. The stock remains a positive watch for growth in the API segment and continued regulatory compliance.
Wanbury Responds to Exchange Query on Missing Q2 FY26 Consolidated Financial Results
Wanbury Limited has submitted a formal response to the Stock Exchange regarding the non-submission of consolidated financial results for the quarter ended September 30, 2025. The Exchange had flagged this as a potential non-compliance with Regulation 33 of SEBI (LODR) Regulations, 2015. This clarification is significant as consolidated results are essential for understanding the performance of the company's subsidiaries alongside its standalone operations. Investors are currently awaiting the full financial picture to assess the group's total debt and profitability.
Key Highlights
Exchange sought clarification for the quarter ended September 30, 2025, regarding missing consolidated data.
The inquiry specifically pertains to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company filed its official response to the Exchange on December 18, 2025.
The discrepancy involves the non-submission of Consolidated Financial Results while standalone results were likely filed.
👀 What to Watch
Investors should monitor the subsequent filing of consolidated results to check for any hidden liabilities or losses in subsidiaries. Any further delay in regulatory compliance could lead to penalties or impact the stock's liquidity.
Wanbury Reports Financial Turnaround: Debt Reduced by 75% and FY25 EBITDA Reaches ₹80 Cr
Wanbury Limited has successfully executed a major financial turnaround, reducing its peak debt of ₹700 crore by approximately 75% and lowering borrowing costs from 22.5% to 12.5%. The company achieved its highest-ever operational EBITDA of ₹80 crore in FY25, driven by a dominant 30% global market share in Sertraline and 11% in Metformin. The formulations business reached financial break-even in 9MFY26, with a scale-up strategy planned for FY27. Future growth is anchored by a pipeline of four new molecule commercializations annually starting in FY27, supported by a ₹127 crore CAPEX plan for FY26-27.
Key Highlights
Debt reduced by ~75% from peak levels with interest rates slashed from 22.5% to 12.5% effective March 2025.
Global market leadership established with a 30% share in Sertraline and 11% share in Metformin APIs.
Formulations segment achieved financial break-even in 9MFY26 after years of turnaround efforts.
Aggressive CAPEX plan of ₹64 Cr for FY26 and ₹63 Cr for FY27 focusing on new product blocks and clean rooms.
Operational EBITDA scaled approximately 3X between FY23 and FY25, reaching a record ₹80 crore.
👀 What to Watch
Investors should focus on the company's transition from a debt-heavy turnaround story to a growth-oriented API player with a de-risked balance sheet. Monitor the successful launch of the new anaesthetic molecule in Q4FY26 as a litmus test for the upcoming high-frequency product launch strategy.
Wanbury Limited Announces Q3 & 9M FY26 Un-audited Financial Results
Wanbury Limited has officially released its un-audited financial results for the third quarter and nine-month period ending December 31, 2025 (FY26). The announcement was communicated via a formal press release dated February 6, 2026. This filing is a standard regulatory requirement providing transparency into the company's recent operational performance. Investors should now examine the detailed profit and loss statements to evaluate the company's growth trajectory in the pharmaceutical sector.
Key Highlights
Release of un-audited financial results for the quarter ended December 31, 2025.
Consolidated and standalone performance for the 9-month (9M) period of FY26 included.
Official press release issued on February 6, 2026, to provide management context.
Compliance with SEBI Listing Obligations and Disclosure Requirements confirmed.
👀 What to Watch
Investors should review the full financial tables for specific trends in revenue and EBITDA margins. Compare the Q3 performance against previous quarters to assess if the company is maintaining its growth momentum.
Wanbury Approves Q3 FY26 Results, Grants 60,000 ESOPs and Allots 47,400 Shares
Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter ended December 31, 2025. The company announced the grant of 60,000 new stock options to employees at an exercise price of ₹130 per share. Additionally, the board approved the allotment of 47,400 equity shares following the exercise of previously vested options, generating ₹4.74 lakh in capital. As a result, the company's total paid-up share capital has increased to ₹34.94 crore.
Key Highlights
Approved un-audited financial results for the third quarter and nine months ended December 31, 2025
Granted 60,000 new stock options under ESOP 2016 at a pricing formula of 50% of the closing market price (₹130 per share)
Allotted 47,400 equity shares of face value ₹10 each to employees upon exercise of vested options
Total paid-up share capital increased from ₹34,89,19,980 to ₹34,93,93,980
Realized ₹4,74,000 in cash from the exercise of 47,400 options
👀 What to Watch
Investors should examine the detailed Q3 financial results separately to evaluate the company's fundamental performance. The current equity dilution from ESOPs is minimal and part of standard employee retention strategies.
Wanbury Approves Q3 Results, Grants 60,000 ESOPs, and Allots 47,400 Equity Shares
Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter and nine months ending December 31, 2025. The company announced a fresh grant of 60,000 stock options to employees at an exercise price of Rs. 130 per share. Additionally, the board allotted 47,400 equity shares following the exercise of vested options under the 2016 ESOP plan. This allotment has marginally increased the company's total paid-up share capital to Rs. 34.94 crore.
Key Highlights
Approved un-audited financial results for Q3 and the nine-month period ended December 31, 2025
Granted 60,000 new ESOPs at an exercise price of Rs. 130 per share, representing 50% of the closing market price
Allotted 47,400 equity shares of Rs. 10 each, realizing Rs. 4,74,000 from the exercise of options
Total paid-up share capital increased from Rs. 34,89,19,980 to Rs. 34,93,93,980
The total number of equity shares outstanding now stands at 3,49,39,398
👀 What to Watch
Investors should review the detailed Q3 financial results once published to evaluate the company's fundamental performance. The current ESOP activity results in negligible equity dilution while serving as an employee retention tool.
Wanbury Achieves First Sales and Commercial Shipment of New Anaesthetic API
Wanbury Limited has successfully commenced commercial shipments of its new high-demand Anaesthetic API from its Tanuku facility in Andhra Pradesh. The first sale and invoicing milestone was achieved on January 30, 2026, for a leading European customer. This move marks the company's entry into a high-growth segment just months after the initial product launch. Management expects this to signal rapid growth and production ramp-up, strengthening its global API portfolio which already serves over 50 countries.
Key Highlights
Achieved first sales and invoicing of a new high-demand Anaesthetic API on January 30, 2026
Commenced commercial shipments to a leading European customer from the USFDA/EUGMP approved Tanuku facility
Commercialization achieved within just months of the product launch, indicating high operational efficiency
Management signals rapid growth ahead with plans to multiply production capacity and scaling fast
👀 What to Watch
Investors should monitor the revenue contribution from this new API in upcoming quarterly results to validate the scale of the production ramp-up. The successful entry into the specialized anaesthetic segment enhances the company's margin profile and global competitiveness.
Wanbury Launches Anaesthetic API Production; Targets ₹100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. This move is expected to generate incremental revenues of approximately ₹18 crore in Q4 FY26 and over ₹100 crore in FY 2026-27. The company is also expanding its capacity with a multi-purpose intermediate block scheduled for completion by March 2026. This expansion aims to capture a share of the global market for these new APIs, which is currently valued at over ₹5,000 crore.
Key Highlights
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over ₹100 crore in FY 2026-27 from the new API production.
Expected immediate revenue contribution of approximately ₹18 crore in Q4 FY 2025-26.
On track to launch four additional high-value APIs (Antidiabetic, Anticoagulant, etc.) by March 2026.
Targets a global market opportunity for these molecules valued at over ₹5,000 crore.
👀 What to Watch
Investors should track the company's ability to scale production and meet the ₹18 crore revenue target in Q4 FY26 as a sign of execution capability. The successful launch of the additional four APIs in March 2026 could be a further re-rating trigger for the stock.
Wanbury Launches Anaesthetic API Production; Targets Rs 100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. The company expects this launch to generate incremental revenues of approximately Rs. 18 crore in Q4 FY26 and over Rs. 100 crore in FY 2026-27. Furthermore, a new multi-purpose production block is on track for completion by March 2026, which will facilitate the production of four additional high-value APIs. These strategic moves target a global market opportunity valued at over Rs. 5,000 crore, significantly strengthening the company's API portfolio.
Key Highlights
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over Rs. 100 crore for FY 2026-27 and Rs. 18 crore for Q4 FY26.
Multi-purpose intermediate production block for four additional APIs expected to be ready by March 2026.
New products target high-value therapeutic categories including Anticoagulants and Antidepressants.
The global market for the upcoming pipeline of APIs is currently valued at over Rs. 5,000 crore.
👀 What to Watch
Investors should track the timely commissioning of the multi-purpose block in March 2026 and the subsequent revenue ramp-up in the coming quarters. The projected revenue growth represents a significant expansion for the company, making it a positive development for long-term shareholders.
Wanbury Limited EGM on January 05, 2026 for Director Re-Appointment
Wanbury Limited is holding an Extraordinary General Meeting (EGM) on January 05, 2026, via video conferencing to re-appoint Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director. The re-appointment is for a term of one year, effective from January 08, 2026, until January 07, 2027. Shareholders can participate through video conferencing, with a facility for at least 1000 members on a first-come, first-served basis. Remote e-voting will be available from January 02, 2026, at 09:00 A.M. to January 04, 2026, at 05:00 P.M.
Key Highlights
EGM to be held on January 05, 2026, at 03:00 P.M.
Re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN- 01064558) as Non-Executive Independent Director
Re-appointment effective from January 08, 2026 upto 07th January, 2027
Remote e-voting begins on January 2, 2026 at 09:00 A.M. and ends on January 4, 2026 at 05:00 P.M.
Cut-off date (record date) of Monday, 29th December, 2025
👀 What to Watch
Shareholders should review the details of the resolution regarding the director's re-appointment and cast their votes via remote e-voting between January 2nd and 4th, 2026. Monitor the company's website for further updates and participation instructions for the EGM.
Wanbury Board Meeting Outcome: Re-appointment of Independent Director
Wanbury Limited's board has approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director for a period of 1 year, effective from January 08, 2026, to January 07, 2027. This re-appointment is subject to shareholders' approval via a special resolution in an upcoming extra-ordinary general meeting to be held on January 05, 2026. Mr. Gursahani has confirmed that he continues to meet the criteria of 'Independence' under the Companies Act, 2013 and SEBI Listing Regulations. The board meeting commenced at 04:30 P.M. and concluded at 05:15 P.M.
Key Highlights
Re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director.
Tenure is for 1 (One) year effective from January 08, 2026 to January 07, 2027.
Extra Ordinary General Meeting (EGM) to be held on Monday, January 05, 2026 for shareholders' approval.
Board meeting commenced at 04:30 P.M. and concluded at 05:15 P.M.
👀 What to Watch
Shareholders should review the details of Mr. Gursahani's profile and consider voting on the resolution for his re-appointment at the EGM on January 05, 2026. Monitor company announcements for further updates.
